

1 **Supplementary Table 1** - Percentage (%) of plasma fatty acids in patients with  
2 hematological malignancies supplemented or not with fish oil during chemotherapy.

MODEL 1						
Fatty Acids	UG-T0	UG-T1	<i>P</i> <sup>#</sup>	SG-T0	SG-T1	<i>P</i> <sup>#</sup>
<b>SFA</b>	50.0 [40.2; 53.0]	40.7 [36.6; 43.9]	<0.01**	36.8 [33.7; 43.5]	37.2 [33.4; 45.2]	0.40
<b>UFA</b>	47.6 [45.2; 57.5]	55.7 [54.6; 61.7]	<0.01**	62.17 [54.1; 64.7]	58.57 [52.6; 63.2]	0.17
<b>EPA</b>	0.5 [0.3; 0.8]	0.6 [0.5; 0.9]	0.07	0.5 [0.4; 1.2]	1.1 [0.9; 1.5]	<0.01**
<b>DHA</b>	0.90 [0.6; 2.4]	0.99 [0.6; 3.0]	0.77	1.1 [0.8; 1.6]	1.8 [1.1; 2.5]	0.07
MODEL 2						
<b>SFA</b>	46.1 [39.6; 52.7]	40.7 [36.5; 43.6]	0.04*	42.6 [36.0; 44.0]	38.9 [35.1; 48.6]	0.97
<b>UFA</b>	52.2 [45.6; 58.8]	57.4 [54.9; 62.3]	0.04*	55.47 [53.7; 62.8]	57.6 [48.1; 61.0]	0.62
<b>EPA</b>	0.5 [0.4; 0.8]	0.6 [0.5; 0.8]	0.10	0.51 [0.4; 1.4]	1.1 [1.0; 2.0]	0.03*
<b>DHA</b>	1.0 [0.8; 2.2]	0.9 [0.5; 2.5]	0.84	1.03 [0.7; 1.5]	1.9 [1.7; 2.7]	0.03*

Data are presented as median [interquartile range]. Model 1 included all eligible patients that accepted to participate and finished the nine weeks of follow-up. Model 2 included patients from SG that presented  $\geq 100\%$  increment in the proportion of plasma EPA and DHA at 9 weeks compared to baseline and UG patients who did not show an increment (< 50%) in plasma EPA and DHA at 9 weeks when compared to baseline. Abbreviations: UG: Unsupplemented group. SG: Supplemented Group. T0 - Data before the first session of chemotherapy; T1 - Data after 9 weeks of chemotherapy. SFA: Saturated Fatty Acids. UFA: Unsaturated Fatty Acids. EPA: eicosapentaenoic fatty acid. DHA: docosahexaenoic fatty acid. #Wilcoxon test comparing T0 and T1 within the same group; \*p<0.05; \*\*p<0.01.